Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH Biobank)

被引:4
|
作者
Charoenpong, Prangthip [1 ,2 ,3 ]
Dhillon, Navneet [4 ]
Murnane, Kevin [2 ,3 ,5 ,6 ]
Goeders, Nicholas [2 ,3 ,5 ,6 ]
Hall, Nicole [5 ]
Keller, Courtney [5 ]
Bhuiyan, Mohammad Alfrad Nobel [2 ,7 ]
Walter, Robert [1 ,2 ,3 ]
机构
[1] Louisiana State Univ Hlth Sci Ctr Shreveport, Div Pulm & Crit Care, Internal Med, Shreveport, LA 71103 USA
[2] Louisiana State Univ, Hlth Sci Ctr Shreveport, Ctr Cardiovasc Dis & Sci, Shreveport, LA 71130 USA
[3] Louisiana State Univ, Louisiana Addit Res Ctr, Hlth Sci Ctr Shreveport, Shreveport, LA 71103 USA
[4] Univ Kansas, Dept Internal Med, Internal Med Pulm & Crit Care, Med Ctr, Kansas City, KS USA
[5] Louisiana State Univ, Hlth Sci Ctr Shreveport, Dept Pharmacol Toxicol & Neurosci, Shreveport, LA USA
[6] Louisiana State Univ, Hlth Sci Ctr Shreveport, Dept Psychiat, Shreveport, LA USA
[7] Louisiana State Univ, Div Clin Informat, Internal Med, Hlth Sci Ctr Shreveport, Shreveport, LA USA
关键词
Drug induced Lung Disease; Primary Pulmonary Hypertension; Rare lung diseases; Clinical Epidemiology; Patient Outcome Assessment; OUTCOMES; INVOLVEMENT; TRANSPORTER;
D O I
10.1136/bmjresp-2023-001917
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
ObjectiveThis study compares the clinical and haemodynamic severity of methamphetamine-associated pulmonary arterial hypertension (MA-PAH) with idiopathic pulmonary arterial hypertension (IPAH) and connective tissue-associated pulmonary arterial hypertension (CTD-PAH). It also examines sex differences in clinical and physiological parameters among those with MA-PAH.DesignThis is a cross-sectional study using clinically derived data from the National Biological Sample and Data Repository for Pulmonary Arterial Hypertension (PAH biobank), a US-based registry, to compare clinical and physiological characteristics between males and females with MA-PAH.PopulationThe analysis included 1830 patients enrolled in the PAH biobank, with a diagnosis of MA-PAH (n=42), IPAH (n=1073), or CTD-PAH (n=715).Main outcome measuresThe study assessed and compared the clinical and haemodynamic parameters of patients with MA-PAH, IPAH and CTD-PAH.ResultsAmong the patients analysed, 42 had MA-PAH, with 69.1% being female. There were no statistically significant differences in functional class among patients with MA-PAH, IPAH and CTD-PAH. The per cent predicted 6-min walk distance (6MWD) was comparable between the three groups. Patients with MA-PAH had similar mean pulmonary artery pressure and pulmonary vascular resistance to patients with IPAH but higher compared with patients with CTD-PAH. Male patients with MA-PAH exhibited a worse functional class and lower per cent predicted 6MWD, but no significant differences in haemodynamic findings were observed between the sexes.ConclusionThere were no differences in haemodynamic between MA-PAH and IPAH but we found that MA-PAH differed from CTD-PAH. The study did not find evidence of sex differences in MA-PAH. Further research is necessary to identify risk factors and underlying mechanisms of MA-PAH, particularly considering the increasing prevalence of methamphetamine use. Such investigations will contribute to the development of effective prevention and treatment strategies for this condition.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Patients with Methamphetamine-Associated Pulmonary Arterial Hypertension Have Less Favorable Hemodynamics Than Other Patients with Group 1 PAH
    Vasti, E.
    Papolos, A.
    Kolaitis, N. A.
    Mayfield, J.
    Tison, G. H.
    De Marco, T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S18 - S19
  • [22] Methamphetamine and uopathic pulmonary arterial hypertension
    Rothman, Richard B.
    Baumann, Michael H.
    CHEST, 2007, 132 (04) : 1412 - 1413
  • [23] Methamphetamine and the risk of pulmonary arterial hypertension
    Ramirez, Ramon L., III
    Perez, Vinicio De Jesus
    Zamanian, Roham T.
    CURRENT OPINION IN PULMONARY MEDICINE, 2018, 24 (05) : 416 - 424
  • [24] Treatment of Pulmonary Arterial Hypertension (PAH): Data from the Quality Enhancement Research Initiative
    McLaughlin, V.
    Langer, A.
    Dragomir, A.
    Casanova, A.
    Altshuler, M.
    Oudiz, R.
    Mathier, M.
    Clements, P.
    Tapson, V.
    Channick, R.
    Rubin, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [25] Survival in patients with pulmonary arterial hypertension: data from the registry - single PAH centre
    Selimovic, N.
    Andersson, B.
    Bech-Hanssen, O.
    Rundqvist, B.
    EUROPEAN HEART JOURNAL, 2011, 32 : 437 - 437
  • [26] Regional Variation in Methamphetamine-associated Pulmonary Arterial Hypertension: Who'd Better Call Saul?
    Prohaska, Clare C.
    Machado, Roberto F.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (04) : 584 - 585
  • [27] Cause of death in patients with idiopathic pulmonary arterial hypertension: data from the Swedish pulmonary arterial hypertension registry
    Hjalmarsson, C.
    Rundqvist, B.
    Multing, J.
    Kylhammar, D.
    Radegran, G.
    Kjellstrom, B.
    EUROPEAN HEART JOURNAL, 2017, 38 : 749 - 750
  • [28] EXPERT CONSENSUS ON THE DEFINITION OF METHAMPHETAMINE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (METH-APAH) AND ASSOCIATED TREATMENT CONSIDERATIONS
    Zamanian, Roham T.
    Kim, Nick H.
    Leary, Peter
    Sargent, Therese
    Kingrey, John
    Adhia, Ankita
    Lopez, David
    Enstone, Ashley
    Perry, Richard
    Bridge, Daisy
    Stone, Medi
    Perrett, Lisa
    Smith, Holly
    Sandros, Marinella
    CHEST, 2024, 166 (04) : 5997A - 5998A
  • [29] METHAMPHETAMINE-ASSOCIATED PULMONARY HYPERTENSION PRESENTING WITH INTERMITTENT DYSPNEA
    Luong, Robert
    Antwi-Amoabeng, Daniel
    Madhani-Lovely, Farah
    CHEST, 2021, 160 (04) : 2212A - 2212A
  • [30] Targeted Therapy of pulmonary arterial Hypertension (PAH)
    Klose, H.
    Opitz, C.
    Bremer, H.
    Ewert, R.
    Bonderman, D.
    Rosenkranz, S.
    Seeger, W.
    Schmeisser, A.
    Harbaum, L.
    Buerke, M.
    Ghofrani, H. Ardeschir
    Borst, M. M.
    Leuchte, H. H.
    Lange, T. J.
    Behr, J.
    Ulrich, S.
    Lang, I.
    Olschewski, H.
    Gall, H.
    Kabitz, H. -J.
    Kleber, F. -X.
    Held, M.
    Hoeper, M. M.
    Gruenig, E.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 : S142 - S150